News Digest / Ticker: BTAI

Ticker: BTAI

08:48am, Wednesday, Aug 27, 2025

BTAI +10%: SERENITY Phase 3 Safety Win Sets Up Q1 2026 sNDA as BioXcel Targets 57-77M At‑Home Episodes

BioXcel (NASDAQ:BTAI) +10% after SERENITY at‑home Phase 3 met its primary safety endpoint for BXCL501 (120μg), supporting a planned sNDA in Q1 2026 to expand IGALMI to at‑home use and boosting US episode estimate to 57-77M.

10:04am, Tuesday, Aug 12, 2025

BioXcel narrows focus to BXCL501 SERENITY as August readout, cash and debt pressure loom

BioXcel Therapeutics, Inc. (NASDAQ: BTAI) - Quick read on what's happening inside Snapshot - what's happening inside the company - Management has materially reprioritized operations: commercial support for IGALMI® has been scaled back and R&D focus shifted to the highest‑priority programs (BXCL50...